PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript

PAVmed held a special meeting of stockholders via webcast on December 5, 2025, led by CEO Lishan Aklog with General Counsel Michael Gordon, outside counsel Eric Schwartz and transfer agent Alwyn Burton present. The excerpt is procedural: it covers housekeeping items including webcast voting (which would revoke prior proxies), Q&A submission instructions, and access to the certified stockholder list; no financial, operational or strategic disclosures are included in the provided text.

Analysis

Market structure: This special shareholder meeting is a governance event — winners are active shareholders and potential acquirers who can extract value via board change or sale; losers are incumbent management and retail holders if the vote triggers dilution or a rights issuance. Expect a binary re-pricing around the vote result: >20–40% intraday moves are realistic for a microcap like PAVM given low float and concentrated ownership. Options IV, borrow rates and intraday volume will spike; bonds/FX/commodities unaffected.

Risk assessment: Tail risks include surprise PIPE dilution, emergency SEC scrutiny or litigation from dissatisfied holders; probability low-to-moderate but impact could be -40%+ in days. Immediate horizon (days) centers on vote outcomes and proxy filings; short-term (weeks) on 8-K disclosures and potential M&A approaches; long-term (quarters) on strategy shifts and cash runway. Hidden dependencies: transfer agent miscounts, record-date technicalities, and insider lockups that change float materially.

Trade implications: Direct: use limited-size event trades — directional via 30–90 day options rather than naked stock — to capture binary skew. Consider a 2–3% portfolio notional in 60–90 day calls if you expect a pro-shareholder outcome, or buy 60-day puts if afraid of dilution. Pair trade: long PAVM call / short IHI (ticker IHI) futures or put spread to isolate idiosyncratic governance risk versus sector beta.

Contrarian angles: Consensus treats this as neutral procedural; miss is the asymmetric payoff — activist wins in microcaps often produce 30–100% upside on settlement, while dilution outcomes destroy value more slowly but decisively. Reaction may be underpriced because retail inertia delays volume; a rapid activist victory or announced sale could create a momentum squeeze. Conversely, management entrenchment could decimate sentiment and trigger large forced selling.

Key Decisions for Investors

• Establish a tactical long option position in PAVM: allocate 2% of portfolio notional to 60–90 day in‑the‑money calls (~0.5–0.7 delta) ahead of the vote (within 7 days); target +50% return, cut losses at -30% if IV-adjusted theta bleed dominates.
• Hedge downside with a contingent put strategy: if any 8‑K or proxy filing indicates dilution or contested litigation, buy 30–60 day PAVM puts equal to 1–2% portfolio notional or initiate a put vertical to cap premium — expect downside >30% in that scenario.
• Relative value: implement a pair trade long PAVM calls vs short IHI futures sized to neutralize sector beta (delta‑hedge weekly); this isolates governance-triggered alpha while keeping sector exposure flat for 30–90 days.
• Reallocate 1–3% from microcap/early‑stage medtech positions into IHI (ticker IHI) or cash to reduce idiosyncratic governance risk until final proxy results and any 8‑K filings are public (monitor within 48 hours of the meeting for triggers).